STAAR’s FDA Expansion Isn’t Enough to Quiet the Bear Case

Forward-Looking Analysis

STAAR Surgical’s investment narrative projects $400.0 million in revenue and $36.5 million in earnings by 2029, yielding a $29.67 fair value estimate that suggests a 23% upside from current levels. While consensus focuses on recovery in China and broader EVO adoption, bearish analysts model a more cautious trajectory, projecting only about 9 percent annual revenue growth and US$28.0 million of earnings by 2029. This divergence highlights concerns regarding the company’s heavy dependence on ICLs and potential technological disruption. The most relevant recent catalyst is the FDA’s expanded age indication for EVO/EVO+ Visian ICLs to 21 to 60 years. This decision broadens the potential patient pool in the United States, supporting growth catalysts around gaining share outside China. However, investors must monitor execution risks tied to distributor, inventory, and demand uncertainties in the largest market, as well as the operational reset under the new permanent CEO.

Historical Performance Review

In the first quarter of 2026, STAAR Surgical reported revenue of $93.52 million, demonstrating steady top-line performance. The company achieved a gross profit of $68.86 million, indicating strong margin retention. Net income reached $5.21 million, translating to an earnings per share (EPS) of $0.10. These figures reflect the ongoing operational adjustments and the foundational strength of the implantable lens franchise as the company navigates market volatility.

Additional News

In early August 2026, STAAR Surgical’s Board appointed Warren Foust as President, Chief Executive Officer, and director. Concurrently, Deborah Andrews moved from the role of Interim Co-CEO to Executive Vice President, continuing as Chief Financial Officer. This leadership change formalizes a structure that had been operating on an interim basis. Foust is credited internally with driving an operational reset and a return to profitable growth. The appointment aims to reinforce investor confidence in STAAR’s execution and governance as it pursues longer-term plans. This consolidation of control under a permanent CEO follows recent strategic developments, including the FDA’s expanded age indication for EVO/EVO+ Visian ICLs. The company continues to navigate concentrated reliance on ICL technology while addressing execution risks in key markets like China.

Summary & Outlook

STAAR Surgical maintains a solid financial foundation with consistent gross margins and positive net income, evidenced by Q1 2026 results. The primary growth catalyst is the FDA’s expanded age indication for EVO/EVO+ ICLs, which broadens the US patient pool and supports share gains outside of China. However, significant risks remain, including heavy dependence on ICL technology and execution challenges in the Chinese market. Analyst forecasts diverge, with optimistic views projecting substantial long-term earnings growth versus bearish models citing limited upside. The formal appointment of CEO Warren Foust signals a commitment to operational stability. Given the mix of regulatory tailwinds and market-specific headwinds, the outlook remains cautiously neutral, with upside potential contingent on successful international execution and sustained demand recovery.